Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
Betsy Goodfellow | April 18, 2024 | News story | Research and Development | Ear Nose & throat, Eli Lilly, clinical trial, sleep apnoea, tirzepatide
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated that tizepatide injection (10mg or 15mg) significantly reduced the apnoea-hypopnea index (AHI) compared to placebo, therefore meeting its primary endpoints.
The drug also met its secondary endpoints of percentage change in AHI in both key studies. The first study assessed the drug in adults with moderate-to-severe OSA and obesity who were not on any positive airway pressure (PAP) therapy for 52 weeks; in this trial the drug led to a mean AHI reduction from baseline of 27.4 events per hour compared to a mean AHI reduction of 4.8 events per hour for placebo.
The second study evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were on and planned to continue to use PAP therapy for 52 weeks. In this trial, the drug led to a mean AHI reduction from baseline of 30.4 events per hour compared to a mean AHI reduction of 6.0 events per hour for placebo.
Jeff Emmick MD PhD, senior vice president of product development at Eli Lilly, commented: “OSA impacts 80 million adults in the US, with more than 20 million living with moderate-to-severe OSA. However, 85% of OSA cases go undiagnosed and therefore untreated. Addressing this unmet need head-on is critical, and while there are pharmaceutical treatments for the excessive sleepiness associated with OSA, tirzepatide has the potential to be the first pharmaceutical treatment for the underlying disease.”
Betsy Goodfellow
Related Content
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
